13F filer · CIK 1697748 ↗
ARK Invest
You are looking at Q1 2020. See the latest, Q2 2026 →
Reported value
$4.01B
+1.2% on the quarter before
Positions
207
12 new · 23 sold out
Top 10
48.2%
of the value
Est. gain
−$520.2M
on stocks held all quarter
Est. return
−15.0%
on those stocks since Q4 2019
Positions as of Mar 31, 2020, from ARK Invest's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q4 2019. Striped tiles are options.
Largest buys
Since Q4 2019, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Roku Inc~$83.0MAdded · 2.5% → 3.7%+949,270 shares
- Invitae Corp~$76.4MAdded · 4.3% → 5.5%+5,585,618 shares
- Illumina Inc~$75.5MAdded · 6.1% → 6.8%+276,286 shares
- Pinterest Inc~$61.0MAdded · 0.8% → 2.2%+3,951,648 shares
- Proto Labs Inc~$60.7MAdded · 2.1% → 3.0%+797,751 shares
- Crispr Therapeutics Ag~$56.4MAdded · 4.5% → 4.5%+1,328,997 shares
- Block~$54.0MAdded · 5.9% → 6.2%+1,030,891 shares
- Everpure~$53.1MNew · 0.0% → 1.3%+4,318,047 shares
- Pagerduty Inc~$45.1MNew · 0.0% → 1.1%+2,607,525 shares
- Xilinx Inc~$37.8MAdded · 2.6% → 3.0%+485,527 shares
Largest sells
Since Q4 2019, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Tesla~$65.7MCut · 7.6% → 7.8%−125,339 shares
- Netflix~$48.8MCut · 1.4% → 0.3%−129,873 shares
- Salesforce~$47.9MCut · 1.9% → 0.5%−332,355 shares
- The Trade Desk~$46.5MCut · 1.8% → 0.1%−241,153 shares
- Twitter Inc~$38.1MCut · 2.4% → 0.9%−1,551,955 shares
- Tencent Holdings Ltd~$34.9MCut · 1.4% → 0.6%−710,485 shares
- MercadoLibre~$26.7MCut · 1.5% → 0.6%−54,606 shares
- Inovio Pharmaceuticals Inc~$21.9MCut · 0.4% → 0.3%−2,947,040 shares
- Nvidia~$20.1MCut · 1.4% → 1.0%−76,327 shares
- Cloudera Inc~$16.1MSold out · 0.4% → 0.0%−1,388,111 shares
Holdings
As of Mar 31, 2020. Changes are in shares against Dec 31, 2019, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| TeslaCommon Stock · shares −17% · price +25.3% | 7.8% | $312.6M | +$63.0M | ||||||||
| Illumina IncCommon Stock · shares +38% · price −17.7% | 6.8% | $274.2M | −$42.7M | ||||||||
| BlockCommon Stock · shares +28% · price −16.3% | 6.2% | $250.3M | −$38.2M | ||||||||
| Invitae CorpCommon Stock · shares +53% · price −15.3% | 5.5% | $220.0M | −$25.9M | ||||||||
| Crispr Therapeutics AgCommon Stock · shares +45% · price −30.4% | 4.5% | $181.8M | −$54.7M | ||||||||
| Stratasys LtdCommon Stock · shares +16% · price −21.1% | 3.9% | $156.2M | −$36.2M | ||||||||
| Roku IncCommon Stock · shares +129% · price −34.7% | 3.7% | $147.6M | −$34.2M | ||||||||
| 2u IncCommon Stock · shares +29% · price −11.5% | 3.6% | $143.4M | −$14.5M | ||||||||
| Intellia Therapeutics IncCommon Stock · shares +17% · price −16.6% | 3.1% | $125.2M | −$21.3M | ||||||||
| Proto Labs IncCommon Stock · shares +99% · price −25.0% | 3.0% | $122.0M | −$20.5M | ||||||||
| Xilinx IncCommon Stock · shares +46% · price −20.3% | 3.0% | $121.0M | −$21.1M | ||||||||
| Zillow Group IncCommon Stock · shares +39% · price −25.7% | 2.8% | $113.8M | −$28.3M | ||||||||
| Editas Medicine IncCommon Stock · shares +20% · price −33.0% | 2.6% | $105.8M | −$43.5M | ||||||||
| Splunk IncCommon Stock · shares +19% · price −15.7% | 2.4% | $95.3M | −$14.9M | ||||||||
| Lendingtree IncCommon Stock · shares +67% · price −39.6% | 2.2% | $87.2M | −$34.2M | ||||||||
| Pinterest IncCommon Stock · shares +238% · price −17.2% | 2.2% | $86.6M | −$5.3M | ||||||||
| Veracyte IncCommon Stock · shares +17% · price −12.9% | 2.0% | $79.4M | −$10.1M | ||||||||
| Compugen LtdCommon Stock · shares +15% · price +21.8% | 1.9% | $75.0M | +$11.7M | ||||||||
| Nanostring Technologies IncCommon Stock · shares −0.1% · price −13.6% | 1.8% | $73.4M | −$11.5M | ||||||||
| AutodeskCommon Stock · shares +113% · price −14.9% | 1.7% | $68.4M | −$5.6M | ||||||||
| Cerus CorpCommon Stock · shares +49% · price +10.2% | 1.6% | $65.1M | +$4.0M | ||||||||
| Materialise NvADR · shares +19% · price +1.4% | 1.6% | $62.8M | +$736,856 | ||||||||
| EverpureCommon Stock · shares New | 1.3% | $53.1M | — | ||||||||
| Pagerduty IncCommon Stock · shares New | 1.1% | $45.1M | — | ||||||||
| Lendingclub CorpCommon Stock · shares +29% · price −37.8% | 1.1% | $43.2M | −$20.3M | ||||||||
| Total · 207 positions | 100% | $4.01B | −$520.2M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q4 2019 to Q1 2020: 195 stocks held throughout, down $520.2M (−15.0%).
- Tesla+$63.0M+25%
- Compugen Ltd+$11.7M+22%
- Inovio Pharmaceuticals Inc+$6.8M+125%
- Nvidia+$4.5M+12%
- Cerus Corp+$4.0M+10%
- Block−$38.2M−16%
- Illumina Inc−$42.7M−18%
- Teladoc Health Inc1:6 split−$43.5M−69%
- Editas Medicine Inc−$43.5M−33%
- Crispr Therapeutics Ag−$54.7M−30%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out, 2 splits read into the share counts.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | $15.40B+20% | SEC ↗ |
| Q1 2026 | May 12, 2026 | $12.86B−15% | SEC ↗ |
| Q4 2025 | Feb 11, 2026 | $15.07B−10% | SEC ↗ |
| Q3 2025 | Nov 12, 2025 | $16.80B+23% | SEC ↗ |
| Q2 2025 | Jul 30, 2025 | $13.64B+37% | SEC ↗ |
| Q1 2025 | May 7, 2025 | $9.99B−17% | SEC ↗ |
| Q4 2024 | Feb 4, 2025 | $12.01B+10% | SEC ↗ |
| Q3 2024 | Oct 31, 2024 | $10.93B−3% | SEC ↗ |
| Q2 2024 | Jul 26, 2024 | $11.27B−22% | SEC ↗ |
| Q1 2024 | Apr 18, 2024 | $14.44B−14% | SEC ↗ |
| Q4 2023 | Jan 17, 2024 | $16.89B+29% | SEC ↗ |
| Q3 2023 | Oct 18, 2023 | $13.07B−13% | SEC ↗ |
| Q2 2023 | Jul 10, 2023 | $15.10B+4% | SEC ↗ |
| Q1 2023 | Apr 17, 2023 | $14.55B+26% | SEC ↗ |
| Q4 2022 | Jan 24, 2023 | $11.54B−20% | SEC ↗ |
| Q3 2022 | Oct 17, 2022 | $14.35B−15% | SEC ↗ |
| Q2 2022 | Jul 11, 2022 | $16.91B−29% | SEC ↗ |
| Q1 2022 | Apr 18, 2022 | $23.96B−28% | SEC ↗ |
| Q4 2021 | Jan 28, 2022 | $33.08B−21% | SEC ↗ |
| Q3 2021 | Nov 12, 2021 | $41.64B−23% | SEC ↗ |
| Q2 2021 | Aug 5, 2021 | $53.74B+7% | SEC ↗ |
| Q1 2021 | May 13, 2021 | $50.34B+34% | SEC ↗ |
| Q4 2020 | Feb 12, 2021 | $37.59B+123% | SEC ↗ |
| Q3 2020 | Oct 30, 2020 | $16.86B+81% | SEC ↗ |
| Q2 2020 | Aug 11, 2020 | $9.30B+132% | SEC ↗ |
| Q1 2020 | May 14, 2020 | $4.01B+1% | SEC ↗ |
| Q4 2019 | Jan 31, 2020 | $3.96B−13% | SEC ↗ |
| Q3 2019 | Nov 12, 2019 | $4.58B+15% | SEC ↗ |
| Q2 2019 | Jul 30, 2019 | $3.97B+13% | SEC ↗ |
| Q1 2019 | May 13, 2019 | $3.50B+42% | SEC ↗ |
| Q4 2018 | Feb 11, 2019 (amended) | $2.46B−26% | SEC ↗ |
| Q3 2018 | Nov 7, 2018 | $3.31B+21% | SEC ↗ |
| Q2 2018 | Aug 7, 2018 | $2.73B+36% | SEC ↗ |
| Q1 2018 | May 14, 2018 | $2.01B+60% | SEC ↗ |
| Q4 2017 | Feb 12, 2018 | $1.26B+53% | SEC ↗ |
| Q3 2017 | Nov 9, 2017 | $819.3M+60% | SEC ↗ |
| Q2 2017 | Aug 11, 2017 | $513.6M+48% | SEC ↗ |
| Q1 2017 | May 15, 2017 | $346.9M+26% | SEC ↗ |
| Q4 2016 | Feb 13, 2017 | $274.9M | SEC ↗ |